Phenotypic markers for cell therapy and related methods

Patent metadata

Field	Value
Publication number	US-12161670-B2
Application number	US-201816770510-A
Country	US
Kind code	B2
Filing date	Dec 7, 2018
Priority date	Dec 8, 2017
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

Abstract

Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.

First claim

What is claimed:

1. A method of treatment, the method comprising administering to a subject having lymphoma or leukemia a unit dose of a therapeutic composition comprising a plurality of CD8 + and/or CD4 + T cells engineered to express a recombinant receptor, wherein the recombinant receptor is a chimeric antigen receptor directed to CD19, wherein:
the plurality of CD8+ and/or CD4+ T cells have been isolated from the peripheral blood of the subject and engineered with the recombinant receptor; and
the unit dose of cells comprises between 1×10 5 and 1×10 8 total recombinant receptor-expressing CD8 + T cells that express CD27 and CCR7 (receptor + /CD8 + /CCR7 + /CD27 + T cells) and/or recombinant receptor-expressing CD4 + T cells that express CCR7 and CD27 (receptor + /CD4 + /CCR7 + /CD27 + T cells).

2. The method of claim 1 , wherein the T cells expressing the recombinant receptor that are surface positive for CD27 and CCR7 are also surface negative for CD45RA.

3. The method of claim 1 , wherein at least 15% of the total receptor + T cells in the composition are receptor + /CD8 + /CCR7 + /CD27 + or receptor + /CD4 + /CCR7 + /CD27 + .

4. The method of claim 1 , wherein, prior to the administering, the method further comprises assaying the therapeutic composition comprising a plurality of CD8 + and/or CD4 + T cells engineered to express a recombinant receptor for the percentage of T cells expressing the recombinant receptor that are surface positive for CD27 and CCR7.

5. The method of claim 1 , wherein the unit dose comprises between 3×10 6 and 2.5×10 7 total receptor + /CD8 + /CCR7 + /CD27 + viable T cells and/or between 3×10 6 and 2.5×10 7 total receptor + /CD4 + /CCR7 + /CD27 + viable T cells, each inclusive.

6. The method of claim 1 , wherein between 15% and 90% of the total receptor + T cells in the unit dose are receptor + /CD8 + /CCR7 + /CD27 + or receptor + /CD4 + /CCR7 + /CD27 + , each inclusive.

7. The method of claim 1 , wherein the defined ratio of receptor*/CD8+/CCR7+/CD27+ T cells to receptor*/CD4+/CCR7+/CD27+ T cells is between 1:3 and 3:1.

8. The method of claim 1 , wherein the unit dose of cells is administered as a plurality of unit doses contained in separate compositions.

9. The method of claim 8 , wherein the separate compositions comprise a first composition comprising one of the CD8 + T cells and the CD4 + T cells and a second composition comprising the other of the CD8 + T cells and the CD4 + T cells.

10. A method for treatment of a subject, the method comprising: (A) assaying an engineered cell composition comprising T cells expressing a recombinant receptor for the percentage of T cells expressing the recombinant receptor that are surface positive for a phenotype that is CD27 and CCR7, wherein the recombinant receptor is a chimeric antigen receptor directed to CD 19, and wherein the T cells have been isolated from the peripheral blood of the subject and engineered with the chimeric antigen receptor; and (B) administering to a subject having lymphoma or leukemia a therapy, the administering selected from: (1) if the percentage of T cells surface positive for the phenotype of cells of the engineered T cell composition is at or above a threshold value, administering to the subject one or more unit doses of cells of the engineered cell composition comprising T cells expressing the recombinant receptor that are surface positive for the phenotype; or (2) if the percentage of T cells surface positive for the phenotype of cells of the engineered T cell composition is below a threshold value, administering a therapy selected from (a) one or more unit doses of cells of the engineered cell composition and an agent capable of increasing expansion, proliferation or efficacy of T cells of the engineered cell composition in the subject, or (b) an increased dose of cells of the engineered cell composition; wherein the threshold value of the percentage of T cells surface positive for the phenotype is about 15 percent of the total number of T cells in the composition or of the total number of T cells in the composition expressing the recombinant receptor that are surface positive for CD27 and CCR7.

11. The method of claim 10 , wherein the unit dose comprises between 3×10 6 and 2.5×10 7 total receptor + /CD8 + /CCR7 + /CD27 + viable T cells and/or between 3×10 6 and 2.5×10 7 total receptor + /CD4 + /CCR7 + /CD27 + viable T cells, each inclusive.

12. The method of claim 10 , wherein between 15% and 90% of the total receptor + T cells in the unit dose are receptor + /CD8 + /CCR7 + /CD27 + or receptor + /CD4 + /CCR7 + /CD27 + , each inclusive.

13. The method of claim 10 , wherein the ratio of receptor*/CD8+/CCR7+/CD27+ T cells to receptor*/CD4+/CCR7+/CD27+ T cells is between 1:3 and 3:1.

14. The method of claim 10 , wherein the unit dose comprises between 1×10 5 and 5×10 8 total CD3 + viable T cells that express the recombinant receptor (receptor + /CD3 + cells) or total CD3 + viable T cells, each inclusive.

15. The method of claim 10 , wherein the unit dose of cells is administered as a plurality of unit doses contained in separate compositions.

16. The method of claim 15 , wherein the separate compositions comprise a first composition comprising one of the CD8 + T cells and the CD4 + T cells and a second composition comprising the other of the CD8 + T cells and the CD4 + T cells.

17. A method of treatment, the method comprising administering to a subject having lymphoma or leukemia a unit dose of a therapeutic composition comprising a plurality of CD8 + and/or CD4 + T cells engineered to express a recombinant receptor, wherein:
the plurality of CD8+ and/or CD4+ T cells have been isolated from the peripheral blood of the subject and engineered with the recombinant receptor; and
the unit dose of cells comprises between 3×10 6 and 2.5×10 7 recombinant receptor-expressing CD8 + T cells that express CD27 and CCR7 (receptor + /CD8 + /CCR7 + /CD27 + T cells) and/or recombinant receptor-expressing CD4 + T cells that express CCR7 and CD27 (receptor + /CD4 + /CCR7 + /CD27 + T cells).

18. The method of claim 17 , wherein at least 15% of the total receptor + cells in the unit dose are receptor + /CD8 + /CCR7 + /CD27 + or receptor + /CD4 + /CCR7 + /CD27 + .

19. The method of claim 17 , wherein between 15% and 90% of the total receptor + cells in the unit dose are receptor + /CD8 + /CCR7 + /CD27 + or receptor + /CD4 + /CCR7 + /CD27 + , each inclusive.

20. The method of claim 17 , wherein the ratio of receptor*/CD8+/CCR7+/CD27+ T cells to receptor+/CD4+/CCR7+/CD27+ T cells is between 1:3 and 3:1.

Assignees

• Juno Therapeutics Inc

Inventors

• Dave Kedar Himanshu
• Devries Todd
• Hause Jr Ronald James
• Larson Ryan P
• Ramsborg Christopher Glen
• Sutherland Claire L
• Yee Nathan K
• Yost Rachel K

Classifications

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• A61K40/11 Primary

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• C07K2319/02

  containing a signal sequence · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title